X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (450) 450
Publication (40) 40
Book Chapter (15) 15
Book Review (6) 6
Conference Proceeding (2) 2
Patent (2) 2
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (225) 225
index medicus (184) 184
oncology (180) 180
male (116) 116
female (110) 110
respiratory system (103) 103
lung neoplasms - pathology (99) 99
middle aged (99) 99
aged (97) 97
lung neoplasms - drug therapy (72) 72
adult (71) 71
lung cancer (70) 70
carcinoma, non-small-cell lung - drug therapy (62) 62
carcinoma, non-small-cell lung - pathology (60) 60
chemotherapy (60) 60
neoplasm staging (60) 60
prognosis (53) 53
lung cancer, non-small cell (49) 49
aged, 80 and over (45) 45
treatment outcome (45) 45
cancer (44) 44
lung neoplasms - diagnostic imaging (41) 41
survival (41) 41
antineoplastic combined chemotherapy protocols - therapeutic use (38) 38
care and treatment (38) 38
non-small cell lung cancer (36) 36
lung neoplasms - mortality (32) 32
nsclc (31) 31
research (31) 31
surgery (30) 30
carcinoma, non-small-cell lung - diagnostic imaging (28) 28
diagnosis (28) 28
lung neoplasms - therapy (28) 28
survival rate (27) 27
analysis (26) 26
carcinoma, non-small-cell lung - mortality (26) 26
cisplatin - administration & dosage (25) 25
positron-emission-tomography (25) 25
staging (25) 25
therapy (25) 25
darbepoetin alfa (24) 24
hematology, oncology and palliative medicine (24) 24
lymphatic metastasis (24) 24
prospective studies (24) 24
antineoplastic agents - therapeutic use (22) 22
carcinoma (22) 22
clinical trials (22) 22
radiotherapy (22) 22
tomography, x-ray computed (22) 22
anemia - drug therapy (21) 21
cell lung-cancer (21) 21
survival analysis (21) 21
carcinoma, non-small-cell lung - therapy (20) 20
docetaxel (20) 20
double-blind (20) 20
erythropoietin - analogs & derivatives (20) 20
fluorodeoxyglucose f18 (20) 20
lung neoplasms - surgery (20) 20
randomized controlled trials as topic (20) 20
tumors (20) 20
antineoplastic agents - adverse effects (19) 19
cisplatin (19) 19
computed-tomography (19) 19
disease-free survival (19) 19
positron-emission tomography (19) 19
quality of life (19) 19
trial (19) 19
health aspects (18) 18
radiology, nuclear medicine & medical imaging (18) 18
anemia - chemically induced (17) 17
lung neoplasms - classification (17) 17
phase-iii trial (17) 17
quality-of-life (17) 17
radiopharmaceuticals (17) 17
antineoplastic combined chemotherapy protocols - adverse effects (16) 16
carcinoma, non-small-cell lung - surgery (16) 16
immunotherapy (16) 16
metastasis (16) 16
non-small-cell lung cancer (16) 16
phase-iii (16) 16
retrospective studies (16) 16
anemia (15) 15
cancer therapies (15) 15
carcinoma, non-small-cell lung - secondary (15) 15
double-blind method (15) 15
induction chemotherapy (15) 15
lung neoplasms - diagnosis (15) 15
lung neoplasms - radiotherapy (15) 15
open-label (15) 15
pemetrexed (15) 15
carcinoma, non-small-cell lung - genetics (14) 14
erythropoietin - therapeutic use (14) 14
fdg-pet (14) 14
multicenter (14) 14
pulmonary/respiratory (14) 14
sensitivity and specificity (14) 14
time factors (14) 14
animals (13) 13
bronchogenic-carcinoma (13) 13
combined modality therapy (13) 13
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 1, pp. 38 - 47
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10030, pp. 1837 - 1846
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 6, pp. 822 - 835
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2018, Volume 378, Issue 2, pp. 113 - 125
In 556 patients with previously untreated lung cancer bearing EGFR mutations, osimertinib and the first-generation EGFR inhibitors erlotinib and gefitinib had... 
1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | PHASE-III | ACQUIRED-RESISTANCE | OPEN-LABEL | CNS RESPONSE | AZD9291 | CHEMOTHERAPY | ERLOTINIB | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Gefitinib | Lung Neoplasms - genetics | Double-Blind Method | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Survival Rate | Piperazines - therapeutic use | Carcinoma, Non-Small-Cell Lung - mortality | Piperazines - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Aged | Erlotinib Hydrochloride - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Treatment outcome | Cancer patients | Care and treatment | Lung cancer, Non-small cell | Analysis | Tyrosine | Medical research | Epidermal growth factor receptors | Lung cancer | Clinical trials | Non-small cell lung carcinoma | Oncology | Metastasis | Gene deletion | Patients | Cancer therapies | Clinical outcomes | Chemotherapy | Epidermal growth factor | Clonal deletion | Protein-tyrosine kinase receptors | Protein-tyrosine kinase | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2018, Volume 379, Issue 24, pp. 2342 - 2350
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2013, Volume 31, Issue 19, pp. 2388 - 2395
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 4, pp. 452 - 463
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2008, Volume 26, Issue 21, pp. 3543 - 3551
Journal Article